Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JCOG1305 INNOVATE-HL
jRCTs031180218Active, not recruiting
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
- Start
- Jan 2016
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Open-label trial of doxorubicin, bleomycin, vinblastine, dacarbazine, etoposide and 5 more in classical Hodgkin lymphoma (cHL) (3 arms), sponsored by Cancer Institute and Hospital, Chinese Academy of Medical Sciences. Primary endpoints: 2-year progression-free survival among all eligible patients and 2-year progression-free survival among interim PET-positive patients. Started Jan 2016; status: active, not recruiting.
02
Drugs
doxorubicinbleomycinvinblastinedacarbazineetoposide
03
Conditions
classical Hodgkin lymphoma (cHL)
Beyond the preview
Go deeper on jRCTs031180218.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs031180218.